Artificial intelligence could benefit all aspects of clinical trials: IQVIA

Clinical research and drug development professionals are largely aware of artificial intelligence (AI), machine learning (ML), and other advanced analytical tools. However, many are not yet aware of their full potential, or how to best put such tools to work. Lucas Glass, vice president of the IQVIA Analytics Center of Excellence, spoke with Outsourcing-Pharma about how the adoption of AI/ML is evolving, what people in the field need to understand, and what might lie ahead. OSP: Could you please tell us what the biggest challenge has been facing professionals in your corner of the life-sciences industry? LG: The biggest challenge facing the industry is user empathy between the technologists and the clinical trial professionals.